Unlocking cancer vaccine potential: What are the key factors?
Hum Vaccin Immunother
; 20(1): 2331486, 2024 Dec 31.
Article
en En
| MEDLINE
| ID: mdl-38564321
ABSTRACT
Cancer is a global health challenge, with changing demographics and lifestyle factors producing an increasing burden worldwide. Screening advancements are enabling earlier diagnoses, but current cancer immunotherapies only induce remission in a small proportion of patients and come at a high cost. Cancer vaccines may offer a solution to these challenges, but they have been mired by poor results in past decades. Greater understanding of tumor biology, coupled with the success of vaccine technologies during the COVID-19 pandemic, has reinvigorated cancer vaccine development. With the first signs of efficacy being reported, cancer vaccines may be beginning to fulfill their potential. Solid tumors, however, present different hurdles than infectious diseases. Combining insights from previous cancer vaccine clinical development and contemporary knowledge of tumor immunology, we ask who are the 'right' patients, what are the 'right' targets, and which are the 'right' modalities to maximize the chances of cancer vaccine success?
Palabras clave
Texto completo:
1
Colección:
01-internacional
Banco de datos:
MEDLINE
Asunto principal:
Vacunas contra el Cáncer
/
COVID-19
/
Neoplasias
Límite:
Humans
Idioma:
En
Revista:
Hum Vaccin Immunother
Año:
2024
Tipo del documento:
Article
País de afiliación:
Reino Unido